Dopamine agonists such as pramipexole, ropinirole, rotigotine, and apomorphine have long been recommended as initial therapy for younger patients with Parkinson’s disease, typically those younger than ...
Parkinson’s disease (PD) is a neurodegenerative disorder characterised by progressive dopaminergic neuronal loss within the substantia nigra pars compacta. The resultant striatal dopamine deficiency ...
PHILADELPHIA — Tavapadon, an experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson's disease (PD), was shown to significantly reduce disease burden in two ...
Mount Sinai researchers have discovered distinct roles for two dopamine receptors located on nerve cells within the portion of the brain that controls approach vs. avoidance behavior. These receptors ...
Different receptors respond to different neurotransmitters or hormones, such as adrenaline involved in the fight-or-flight response, or dopamine linked to reward and motivation. Both the receptors ...
Parkinson's Disease Clinical Trial Pipeline Boom as 150+ Companies are in the Race for Better Treatments | DelveInsight DelveInsight's 'Parkinson's Disease Pipeline Insight 2026' report provides ...
– ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – ...
A study using positron emission tomography (PET) imaging has found that patients with schizophrenia had significantly lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results